SECURITIES AND EXCHANGE COMMISSION
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported) April 27, 2004 (April 26, 2004)
REGENERON PHARMACEUTICALS, INC.
NEW YORK | 0-19034 | No. 13-3444607 | ||
|
||||
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY | 10591-6707 | |
|
||
(Address of principal executive offices) | (Zip Code) |
Registrants telephone number, including area code | (914) 347-7000 | ||
|
NOT APPLICABLE
Page 1 of 9
INFORMATION TO BE INCLUDED IN REPORT | ||||||||
Item 7. Financial Statements and Exhibits. | ||||||||
Item 12. Results of Operations and Financial Condition. | ||||||||
SIGNATURE | ||||||||
PRESS RELEASE |
INFORMATION TO BE INCLUDED IN REPORT
Item 7. Financial Statements and Exhibits.
(c) | Exhibits | |
99(a) Press Release dated April 26, 2004. |
Item 12. Results of Operations and Financial Condition.
On April 26, 2004, we reported our first quarter 2004 results. Our first quarter 2004 results are discussed in detail in the press release attached hereto as Exhibit 99(a), which is incorporated by reference in its entirety. The information furnished under Item 12 of this Current Report on Form 8-K, including Exhibit 99(a), shall be deemed filed for purposes of the Securities Exchange Act of 1934, as amended and incorporated by reference in any of our filings under the Securities Act of 1933, as amended, as may be specified in such filing.
-2-
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Regeneron Pharmaceuticals, Inc. | ||
By: /s/ Murray A. Goldberg |
||
Murray A. Goldberg Senior Vice President, Finance and Administration, Chief Financial Officer, Treasurer & Assistant Secretary |
||
Date: April 27, 2004 |
-3-